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ABSTRACT
This review discusses an approach to determining the
cause of neonatal encephalopathy, as well as current
evidence on resuscitation and subsequent management
of hypoxic-ischaemic encephalopathy (HIE).
Encephalopathy in neonates can be due to varied
aetiologies in addition to hypoxic-ischaemia. A
combination of careful history, examination and the
judicious use of investigations can help determine the
cause. Over the last 7 years, infants with moderate to
severe HIE have beneﬁted from the introduction of
routine therapeutic hypothermia; the number needed to
treat for an additional beneﬁcial outcome is 7 (95% CI
5 to 10). More recent research has focused on optimal
resuscitation practices for babies with cardiorespiratory
depression, such as delayed cord clamping after
establishment of ventilation and resuscitation in air.
Around a quarter of infants with asystole at 10 min after
birth who are subsequently cooled have normal
outcomes, suggesting that individualised decision
making on stopping resuscitation is needed, based on
access to intensive treatment unit and early cooling. The
full beneﬁt of cooling appears to have been exploited in
our current treatment protocols of 72 hours at 33.5°C;
deeper and longer cooling showed adverse outcome. The
challenge over the next 5–10 years will be to assess
which adjunct therapies are safe and optimise
hypothermic brain protection in phase I and phase II
trials. Optimal care may require tailoring treatments
according to gender, genetic risk, injury severity and
inﬂammatory status.
Neonatal encephalopathy (NE) is deﬁned as a condi-
tion occurring in babies born over 35 weeks gesta-
tional age in which there is disturbed neurological
function. The key feature is the disturbance in the
degree or quality of consciousness; other features,
such as seizures, cardiorespiratory compromise or
abnormal tone and reﬂexes, may occur alongside it
but are not necessary to make the diagnosis.1 In
2014, the Task Force on Neonatal Encephalopathy
published new guidelines on criteria for retrospect-
ive deﬁnition of an intrapartum event sufﬁcient to
cause cerebral palsy (CP).1 The title of the report
was changed from Neonatal Encephalopathy and
Cerebral Palsy to Neonatal Encephalopathy and
Neurological Outcome to emphasise that there are
many causes of encephalopathy in a newborn baby
and that an array of developmental outcomes may
arise in addition to CP. Knowledge gaps preclude a
deﬁnitive test or set of markers that accurately iden-
tiﬁes, with high sensitivity and speciﬁcity, an infant
in whom NE is attributable to an acute intrapartum
event. The term NE should be used where no
deﬁnite aetiological diagnosis is known, and
hypoxic-ischaemic encephalopathy (HIE) where
clear diagnosis of hypoxia-ischaemia is known to
have led to the neonate’s clinical state.
DETERMINING THE AETIOLOGY OF NE
The initial stages of managing NE will be the same
for most babies, with good resuscitation and sup-
portive management. However, as the picture
evolves and investigations return, clinicians should
consider the aetiology of NE as this could lead to
speciﬁc treatments, aid with prognosis and recur-
rence risk counselling, and assist with the evalu-
ation of medicolegal implications.
The other aetiologies to consider include:
▸ Acquired conditions, such as congenital infec-
tion, meningitis, haemorrhage, ischaemic or
haemorrhagic stroke
▸ Genetic syndromes or isolated gene conditions
▸ Neurometabolic disorders, particularly where
the stress of delivery leads to decompensation
▸ ‘Double trouble’ pathologies where a primary path-
ology leads secondarily to a hypoxic-ischaemic
brain injury, like neuromuscular or cardiac
disorders
▸ The neonatal epilepsy syndromes and vitamin
responsive seizures
▸ Non-accidental injury
Assessment should include a detailed history and
neonatal examination, possibly parental examin-
ation, and the judicious use of investigations.
History and examination
A history should be obtained from the mother or, if
not possible, a review of the medical/antenatal
notes or history from the extended family. Salient
features to identify are summarised in box 1. The
following are recommended: a three-generation
family tree, with focus on miscarriages, stillbirths,
child or early adult deaths, ‘cerebral palsy’, learning
difﬁculties, seizures, encephalopathy, metabolic
conditions and early onset ischaemic strokes.
A detailed examination of the baby is needed,
including a neurological assessment, and repeated
neurological examination may be required, as signs
can change quickly. Where a neuromuscular dis-
order is possible, the parents should be examined.
Important features to identify in the examination
are summarised in box 1, and neonatal features
suggestive of a metabolic disorder in box 2.2
First line investigations
Routine ﬁrst line bloods are shown in table 1.
These basic tests will also allow calculation of the
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Box 1 Features to look out for in history and examination
Pregnancy/labour history:
▸ Was there an acute event occurring around the time of birth, such as non-reassuring or abnormal trace on cardiotocograph,99
antepartum haemorrhage, placenta previa, cord prolapse?
▸ Fetal growth on antenatal scans
▸ Fetal abnormalities on ultrasound scan or antenatal MRI
▸ Was this a multiple pregnancy (twins, triplets, etc)?
▸ Maternal infections or carriage of group B Streptococcus
▸ Maternal hypertension
▸ Pre-eclampsia
▸ HELLP syndrome, particularly if associated with acute fatty liver inﬁltration, may indicate long chain 3 hydroxyacyl-coenzyme A
dehydrogenase (LCHAD) deﬁciency2
▸ Maternal hypotension
▸ Maternal prescribed drug use
▸ Maternal illicit drug use, particularly cocaine
▸ Illness during pregnancy, such as may occur in viral infections that may affect the fetus
▸ Gestational diabetes
▸ Trauma, such as accidental falls or road trafﬁc accident, and inﬂicted (assault)
▸ Evidence of maternal haemorrhage
▸ Any predisposing features to a non-accidental injury of baby, if presenting following normal period of consciousness?
Maternal past medical history:
▸ Multiple miscarriages, stillbirths or neonatal deaths—consider genetic, thrombophilia and metabolic causes
▸ Diabetes: associated with brain injuries, such as fetal thrombotic vasculopathy and postnatal hypoglycaemia
▸ Deep vein thrombosis or other clotting disorders: suggestive of thrombophilia or clotting disorder and classical homocystinuria
▸ Arterial ischaemic stroke: suggestive of thrombophilia or vascular abnormalities, such as COL4A1 gene mutations
▸ Learning difﬁculties: suggestive of genetic/metabolic disorder, including myotonic dystrophy which may lead to secondary hypoxic brain
injury
▸ ‘Family history of cerebral palsy’: suggestive of vascular abnormalities, such as COL4A1 gene mutations, or thrombophilia
▸ Cataracts: may indicate inborn error of metabolism, myotonic dystrophy, COL4A1 mutations
▸ Stiffness or startling: consider myotonic disorders or hyperekplexia
▸ Weakness or muscle fatigue: consider neuromuscular problem like myasthenia gravis or congenital myaesthenic syndrome, especially if
ophthalmoplegia or unexplained squint present. If muscle aches, pains and tetany exist, consider maternal hyperparathyroidism
▸ Features of autoimmune disorder: involvement of several endocrine abnormalities, rash or other skin abnormalities like Raynaud’s
syndrome, eye and kidney abnormalities, muscle aches and pains, heart block
▸ Distal weakness of hands or feet, or abnormally shaped toes: consider peripheral neuropathy
Examination of the parents
This is important where a neuromuscular disorder is suspected.
▸ Neuropathies—reduced strength distally, suppressed or absent reﬂexes, abnormally shaped feet/toes, possible loss of sensation in
either parent
▸ Myopathies—proximal weakness, reduced reﬂexes and normal sensation in either parent
▸ Neuromuscular junction defects like maternal myasthenia gravis or myaesthenic syndromes—fatigue/weakness on repeated or
prolonged testing of grip strength, upward eye gaze or ptosis
▸ Maternal myotonia in congenital myotonic dystrophy.
Neonatal examination
▸ Head circumference abnormalities
▸ Dysmorphic features
▸ Abnormal fontanelle shape or size
▸ Features suggestive of a metabolic condition (box 2)2
▸ Rashes suggestive of immune, metabolic conditions or clotting disorders Family History of cerebral palsy:
▸ External and internal ophthalmoplegia
▸ Facial weakness
▸ Features of peripheral involvement, with weakness and reduced reﬂexes
▸ Features of spinal involvement—difﬁcult vaginal birth, mixed upper and lower motor neuron ﬁnding, sensory level, urinary retention,
constipation
▸ Neonatal hypertonia—while neonates with hypoxic-ischaemic encephalopathy can exhibit hypertonia, tremor, myoclonus and
shivering following birth, especially during hypothermia treatment, these usually resolve. A baby who is hypertonic from birth and
remains stiff is unlikely to have experienced hypoxic-ischaemic encephalopathy. An approach to the diagnostic evaluation of
hypertonic neonates has been proposed previously.2a
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anion gap ((serum sodium+potassium)—(serum bicarbonate
+chloride)), with the normal value being <16. Where a clear
history of an antenatal /intrapartum event exists, and the clinical
presentation, course and ﬁrst line investigations point towards
HIE, no further aetiological investigations are required,
although neuroimaging will provide prognostic information.
Second line investigations where HIE is not conﬁrmed
While metabolic conditions do have speciﬁc features (box 2) these
overlap and gestalt diagnosis is difﬁcult.2 Therefore, the diagnostic
approach relies on further investigations, tailored to the clinical
picture.2–4 We don’t advise a scattergun approach to investiga-
tions. A suggested diagnostic algorithm is presented in ﬁgure 1.
Features to identify include:
▸ Where a persistent metabolic acidosis with a raised anion gap
is seen, look at the lactate:
– If the lactate has returned to normal, an organic acidaemia
should be considered when urinary ketones are present.
– If the lactate is persistently high and glucose low, a fatty
acid oxidation defect or organic acidaemia is possible.
– If the organic acids are normal, consider mitochondrial
disease, pyruvate metabolism disorders and some of the
glycogen storage disorders.
▸ If no persistent metabolic acidosis is noted, study the blood
glucose:
– Persistent hypoglycaemia with low urinary ketones and
raised plasma free fatty acids suggests a fatty acid oxida-
tion defect or ketogenesis defect. Plasma or dried blood
spot acylcarnitine proﬁle would be of diagnostic value for
fatty acid oxidation defect and various organic acidurias.
– Persistent hypoglycaemia with low urinary ketones and
plasma free fatty acids suggests hyperinsulinism.
– Note that hypoglycaemia can be associated with mildly
raised serum ammonia.
▸ Very high serum ammonia suggests urea cycle disorders or
other metabolic conditions associated with secondary hyper-
ammonaemia. Advice should be sought from the local meta-
bolic team.
Table 1 Early investigations to assess neonatal encephalopathy
First line investigations Comment
Full blood count May suggest infection, haemorrhage, thrombocytopenia.
Clotting Clotting disorders may be seen in HIE and sepsis, but should also lead the clinician to think about anaemia secondary to
inherited coagulation disorders and intracranial haemorrhage.
Direct Coombs test Evidence of haemolysis.
Liver function test May be abnormal in HIE but is usually transient unless a severe insult to the liver has occurred. Abnormal liver function tests can
be a feature of bilirubin encephalopathy, metabolic conditions, congenital infections, and acute sepsis with bacteria and viruses,
including herpes simplex virus.
Urea and electrolytes May be impaired if the kidneys have had an ischaemic insult but usually improves, unless severe ischaemic injury has occurred.
May also be impaired in congenital abnormalities of the kidneys, metabolic conditions.
Whole blood glucose (rather than
serum glucose as the latter is around
15% higher than whole blood)
Hypoglycaemia may be seen following HIE, but is usually correctable with appropriate treatment. Persistently low glucose requires
further evaluation.
Blood lactate Lactate is often measured on the blood gas, and may increase rapidly to high levels following HIE, but usually falls within days
and returns to normal. A persistently high lactate should trigger further investigations.
Neurophysiology Amplitude integrated EEG (aEEG) using a cerebral function monitor and/or serial standard EEGs to identify seizures and monitor
recovery of encephalopathy. Will also help diagnose neonatal epilepsy syndromes.
Second line investigations to consider ordering which are available quickly (if concerned this is not typical HIE)
Urinary ketones Urinary ketones, when present, in a neonate indicate the use of intermediary pathways of metabolism and are almost
pathognomonic of the presence of a metabolic disorder.
Ammonia In very sick neonates, ammonia, up to about 110 μmol/L may be present. Very high levels (>200 μmol/L) usually indicate a
metabolic cause, for example, urea cycle defect and warrants further investigations.
HIE, hypoxic-ischaemic encephalopathy.
Box 2 Features on examination suggestive of metabolic
aetiology2
Dysmorphia
▸ Large fontanelle
▸ Large, prominent forehead
▸ Hypertelorism
▸ Mid-face hypoplasia
▸ Epicanthic folds
▸ Flat nasal bridge
▸ Long philtrum
▸ Unusual nose, upturned/ﬂared alae nasi
▸ Ear abnormalities, including low set and external
abnormalities to pinna
▸ Genital abnormalities
▸ Limb shortening
▸ Clinodactyly/syndactyly
▸ Abnormal feet, such as rocker-bottom
▸ Abnormal, inverted nipples
▸ Abnormal fat pads
Head size
▸ Microcephaly
▸ Macrocephaly
Liver involvement
▸ Hepatomegaly
▸ Jaundice
Cardiac
▸ Failure/cardiomyopathy
▸ Abnormal ECG
Eye abnormalities
▸ Cataracts
▸ Retinitis pigmentosa (noted on ophthalmology review)
▸ Cherry red spots
▸ Optic atrophy
▸ Lens dislocation
Fetal hydrops
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Figure 1 Continued
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Figure 1 Flow chart to help to determine the cause of neonatal encephalopathy where the history and courses are not typical of hypoxia
ischaemia. aAASA, alpha amino adipic semialdehyde; aEEG, amplitude integrated EEG; CK, creatine kinase; CSF, cerebrospinal ﬂuid; cUSS, cranial
ultrasound scan; DCT, direct Coombs test; EEG, electroencephalogram; EMG; electromyography; FH, family history; FBC, full blood count; GABA,
Gaba-aminobutyric acid; HIE, hypoxic-ischaemic encephalopathy; LFT, liver function test; IV, intravenous; NH3, ammonia; OA, organic acids; U&E,
urea and electrolytes; WBC, white blood cell count; VLCFA, very long chain fatty acids.
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▸ Where no metabolic acidosis, hypoglycaemia or hyperammo-
naemia are found, consider a peroxisomal disorder (request
very long chain fatty acids, phytanic acid and pristanic acid),
or a congenital disorder of glycosylation, where inverted
nipples, unusual fat pads or cerebellar involvement are seen.
To diagnose the latter, the serum transferrin pattern obtained
by automated isoelectric focusing should be ordered towards
the end of the ﬁrst month of life, as earlier samples are con-
taminated by mother’s results.
Not all neonates with encephalopathy have seizures, but those
that do have additional differential diagnoses (ﬁgure 1). These
have been reviewed elsewhere.5 In brief, we recommend for
refractory seizures:
▸ A trial of pyridoxine intravenously and, if no response is
seen, a trial of enteral pyridoxal phosphate alongside either
enteral or intravenous biotin and calcium folinate
▸ Investigations for the vitamin responsive epilepsies (ﬁgure 1)5
▸ Paired serum and cerebrospinal ﬂuid (CSF) lactate to help
identify mitochondrial disorders
▸ Paired serum and CSF amino acids to diagnose non-ketotic
hyperglycinaemia and serine deﬁciencies
▸ Serum uric acid, urinary sulphites, purines and pyrimidines
to diagnose molybdenum cofactor and sulphite oxidase deﬁ-
ciencies and purine/pyrimidine abnormalities
▸ Very long chain fatty acids, phytanic acid and pristanic acid
to diagnose peroxisomal disorders
▸ Copper and caeruloplasmin to diagnose Menkes disease
▸ CSF neurotransmitters if cerebral folate deﬁciency and other
neurotransmitter disorders are possible
Where no diagnosis is found, this may be an unusual presentation
of HIE or an undiagnosed neurological/metabolic/genetic disorder.
Where refractory seizures are present but all aetiological investiga-
tions are negative, we recommend sending DNA for analysis with an
early epileptic encephalopathy gene panel or gene exome studies.
ADVANCES IN THE MANAGEMENT OF HIE
Resuscitation
Around 85% of term babies will breathe spontaneously at birth
without assistance, 10% will require stimulation, 3% will require
non-invasive ventilation, 2% will be intubated and 0.1% will
need chest compressions and/or adrenaline administration.6 It is
important that skilled personal attend births, and in the case of
concerning antenatal or intrapartum events, staff members with
advanced neonatal resuscitation and airway skills are present. A
key component in the resuscitation of the asphyxiated newborn
is to establish functional residual capacity (FRC), and in doing so,
enable return of spontaneous circulation (ROSC) and transition.
Aeration of the previously ﬂuid-ﬁlled lungs is necessary to reduce
pulmonary vascular resistance (PVR) and increase pulmonary
blood ﬂow. Pulmonary blood ﬂow is vital for both oxygenation
and for cardiac output, as it replaces umbilical venous return as
the source of preload to the left ventricle.7
After the cord is clamped in an apnoeic infant with sustained
circulation, there is a 50% reduction in cardiac output, secondary
to the sudden increase is systemic vascular resistance and the per-
sistence of high PVR. Cardiac output is re-established with venti-
lation onset.8 For the infant who is already hypoxic, this time
before establishment of FRC could exacerbate ischaemic injury.
Ventilation prior to cord clamping has been shown to ameliorate
swings in cardiac output and cerebral perfusion9 and Kluckow
and Hooper8 propose delaying cord clamping until after ventila-
tion onset. This would require a signiﬁcant change to delivery
room practice, requiring close collaboration between obstetric
and neonatal staff. The current 2015 European and UK Neonatal
Life Support (NLS) guidelines as well as the International Liaison
Committee on Resuscitation (ILCOR) recommendation recom-
mend delayed cord clamping of at least a minute in infants not
requiring resuscitation;6 10 further research needs to determine
whether resuscitating the asphyxiated infant with the cord
unclamped is of beneﬁt. Stripping (or ‘milking’) of the cord is
not recommended as a routine measure except in the context of
further randomised trials.
The optimal ventilation strategy to achieve FRC and subse-
quently transition in the apnoeic infant is unclear. European
guidelines recommend the use of 5 3-second inﬂation breaths,
whereas American guidelines support conventional ventila-
tion.10 A more prolonged (20–30 second) sustained inﬂation
breath has been shown to hasten ROSC and transition in an
asphyxiated animal model compared with conventional or
‘short’ sustained inﬂations.11 However, sustained inﬂation
resulted in a faster and greater increase in cerebral oxygen deliv-
ery and was associated with an increase in cerebral extravasation
and blood vessel disruption in asphyxiated lambs.12 There is
therefore insufﬁcient evidence to support the use of prolonged
sustained inﬂations for the resuscitation of the asphyxiated
infant and 5 3-second inﬂation breaths should be given.10
The concentration of oxygen used for resuscitation has been a
focus of recent research. The toxicity of resuscitation in 100%
oxygen is now well established. A meta-analysis of 2133
babies13 revealed a reduction in mortality for infants resusci-
tated in 21% versus 100% oxygen (relative risk (RR) 0.69, 95%
CI 0.54 to 0.88) and a trend towards a reduction in HIE. In
animal models of neonatal asphyxia, resuscitation with 21%
versus 100% oxygen resulted in comparable or improved out-
comes of death, neurobehavioural disability and cell death.14 In
an asphyxiated lamb model, 100% versus 21% oxygen for
resuscitation caused an increase in cerebral blood ﬂow (this is
counterintuitive as cerebral vasoconstriction is the typical
response with oxygen).15 The hypoxic brain may have lost auto-
regulatory abilities and be ‘pressure passive’, increasing the risk
of hyperoxia and ﬂow mediated brain injury. There are no clin-
ical studies investigating the beneﬁt of additional oxygen com-
menced during resuscitation, for the infant needing extensive
measures, that is, chest compressions.6 The current ILCOR rec-
ommendation6 is for resuscitation of all term infants to com-
mence in air, and for this to be increased for the infant failing
to achieve ROSC with active measures. It is suggested to reduce
the oxygen content as soon as the heart rate has recovered. The
concentration of oxygen to administer is unknown, and is an
area for ongoing research. The European NLS guidelines
suggest the use of pulse oximetry especially for deliveries where
the infant is anticipated to have problems;10 based on normative
data, the following is a guide to the acceptable preductal oxygen
saturation (SpO2) targets during resuscitation—2 min after birth
60%, 3 min 70%, 4 min 80%, 5 min 85% and 10 min 90%.16
The updated 2015 European NLS guidelines suggest that
attempts to aspirate meconium from the nose and mouth of the
unborn infant, while the head is still on the perineum, are not
recommended and initiating lung inﬂation within the ﬁrst
minute of life in non-breathing or ineffectively breathing infants
should not be delayed. It is reasonable to inspect the orophar-
ynx rapidly to remove potential obstructions but tracheal intub-
ation should not be routine in the presence of meconium.10
The use of adrenaline during neonatal resuscitation is consid-
ered standard care for the infant with a heart rate <60 bpm
who has failed to respond to adequate ventilation and chest
compressions. Evidence for this practice is based on historical
case series and extrapolated from paediatric and adult studies.17
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A recent study in asphyxiated lambs supports the use of adren-
aline in the newborn, demonstrating that chest compressions
alone failed to achieve an increase in mean carotid blood ﬂow,
and that adrenaline was necessary to increase diastolic and mean
carotid (and likely coronary) blood pressure, and subsequently
achieve ROSC.18 The recommended intravenous dose for adren-
aline is 10 μg/kg (0.1 mL/kg of 1:10 000 solution). If this is not
effective, a dose of up to 30 μg/kg (0.3 mL/kg of 1:10 000 solu-
tion) may be tried.10 Endotracheal adrenaline at higher doses
(50–100 μg/kg) may be used when the intravenous route is not
available.10 17 Sodium bicarbonate is not recommended during
brief resuscitation. If it is used during prolonged arrests, it
should be given only after adequate ventilation and circulation
(with chest compressions) is established. The dose for sodium
bicarbonate is between 1 mmol and 2 mmol of bicarbonate /kg
(2–4 mL/kg of 4.2% bicarbonate solution). Hypoglycaemia may
occur in the delivery suite and is known to exacerbate injury;
glucose should be considered if there has been no response to
other drugs delivered through a central venous catheter (the
dose for glucose (10%) is 2.5 mL/kg (250 mg/kg)).10
In the past, guidelines suggested discontinuation of neonatal
resuscitation at 10 min in an infant with persisting asystole
despite adequate resuscitation. This was based on data from the
pre-therapeutic hypothermia era showing high mortality and
neurodevelopmental impairment in survivors with ROSC after
10 min. More recent publications have shown an improvement
in outcome for infants with an Apgar score of 0 at 10 min, for
both cooled and non-cooled infants. Rates of survival without
disability were 20.5% (normothermia) to 27% (cooled) at
24 months in a recent meta-analysis19 and 20.8% at 6–7 years in
follow-up of the NICHD cooling trial.20 The 2015 ILCOR con-
sensus on science and 2015 European NLS guideline continues
to support discontinuation at 10 min, although advises individua-
lised decision making taking into consideration adequacy of
resuscitation, access to cooling and parental opinion.6 10
For infants requiring and surviving extensive resuscitation,
early thought should be given to therapeutic hypothermia, dis-
cussed in further detail below. Therapeutic hypothermia is most
effective when commenced as close as possible in time to the
hypoxic-ischaemic event. Our practice and recommendation is
to maintain normothermia (avoiding hyperthermia) until a deci-
sion to treat with cooling is made by a senior clinician. Passive
cooling can then be started as soon as possible, typically in the
delivery room by turning off radiant heaters. Active cooling can
then be commenced in the neonatal unit. For infants born in
centres not providing intensive care, infants should be promptly
discussed with a tertiary neonatal unit. Cooling should be com-
menced as soon as possible at the referring centre, and/or by the
transport service. A clinical practice guideline for cooling in
transport is available.21 A recent clinical trial in the transport
setting demonstrated that active cooling using a servo controlled
device resulted in a greater number of babies achieving the
target temperature than with passive cooling.22
The term HIE is used from this point as it is assumed other
possible aetiologies of encephalopathy are excluded.
Supportive care
Infants with HIE may have a degree of multiorgan dysfunction.
The hypoxic fetus will initiate the diving reﬂex to preserve
blood ﬂow to vital organs, including brain, heart and adrenals,
at the expense of ﬂow to skin, splanchnic vessels, liver and
kidneys.23 Supportive care to the infant with HIE in the neo-
natal intensive care unit should reﬂect possible hypoxic damage
to the organs and be individually tailored.
Acute tubular necrosis and syndrome of inappropriate anti-
diuretic hormone are common, as is deranged liver function.
Parenteral ﬂuids should be restricted initially as infants will be oli-
guric; we would restrict ﬂuids to 40 mL/kg/day typically until the
urine output starts to increase. We administer parenteral nutrition
through a central venous catheter. Trophic feeds may be started
as colostrum becomes available; typically the feed volume does
not increase above trophic feeds until after rewarming when the
infant is less sedated. Medications requiring renal and hepatic
metabolism, especially those with nephrotoxicity, should be used
cautiously. Hyperglycaemia and hypoglycaemia should be
avoided, as both are associated with long-term disability at
18 months or death in infants with moderate to severe HIE.24
Some studies suggest the particular association of hypoglycaemia
with adverse outcome25 and the operational threshold for taking
steps to raise the blood glucose is higher in infants with HIE
than healthy term infants (>2.5 mmol/L vs >2.0 mmol/L).
Coagulopathy due to hypoxic-ischaemic injury to the liver and
bone marrow may occur. Additionally hypothermia reduces
platelet aggregation, reduces enzymatic function in the coagula-
tion cascade and can trigger disseminated intravascular coagula-
tion. Coagulation studies should be monitored daily during
cooling as laboratory evidence of coagulopathy is universal in
babies with HIE, undergoing cooling. Transfusion strategies to
maintain platelet counts >130×109/L, ﬁbrinogen >1.5 g/L and
INR <2 may prevent clinical bleeding.26
Hypotension is observed in up to 62% of infants with HIE;
inotropic support for HIE has been recently reviewed.27
Cardiac troponins I and T are established markers of myocardial
ischaemia and cardiac failure in adults, children and neonates.
In HIE, troponin T levels have been shown to reach a peak on
day 1, remain elevated for the ﬁrst week and correlate with the
severity of HIE.28 Therapeutic hypothermia reduces cardiac
output by 67% and an increase in support will usually be
required doing the cooling period.27
Factors contributing to pulmonary dysfunction are impaired
central respiratory control, pulmonary injury, persisting pul-
monary hypertension (PPHN) and meconium aspiration.
Adequacy of ventilation should be closely monitored and PaO2
and partial pressure of carbon dioxide kept within normal
range. Acidosis and hypoxia should be corrected to avoid add-
itional brain injury and PPHN; hyperoxia and hypocarbia
should be avoided as they are detrimental to long-term
outcome29 30
Seizure management
Seizures are a common feature of HIE; however, it should be
noted that around 34% of neonatal seizures have clinical features
that can be seen, and only 27% of those were correctly identiﬁed
by neonatal staff. In addition, over 70% of what are thought to
be seizures are not associated with epileptiform discharges on
electroencephalogram (EEG), highlighting the importance of
neurophysiological monitoring.31 In HIE, seizures usually occur
on day 1, and those seen prior to 6 hours of age should raise sus-
picion of earlier in utero insult. Seizures increase cerebral meta-
bolic demand, trigger release of excitatory neurotransmitter and
cause cardiorespiratory instability, all exacerbating neuronal
injury. Increased seizure burden has been signiﬁcantly independ-
ently associated with more severe injury on MRI (OR 5.00, 95%
CI 1.47 to 17.05, p=0.01)32 and with poorer scores on neurode-
velopmental follow-up at 18 months.33 Therapeutic hypothermia
reduces seizure burden in infants with mild–moderate, but not
severe HIE.34 A rebound increase in seizures can be seen with
rewarming.32
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There are no universal guidelines for the management of sei-
zures in neonatal HIE with strategies differing between centres.
Status epilepticus and frequent seizures should be treated,
although there is debate about whether to treat less frequent sei-
zures, or electrographic only (ie, not clinically apparent) sei-
zures. In one study treatment of electrographic seizures using
amplitude integrated EEG (aEEG), compared with treatment of
clinical seizures (aEEG concealed) was associated with lower
seizure burden and less severe MRI injury rating scores.
However there was no difference in developmental outcome at
18 months.33
The ﬁrst line anticonvulsant drug is phenobarbitone,35 although
this will only control seizures in 50% of neonates.36 Common
second line agents include phenytoin, benzodiazepines, and in
Europe, lidocaine. Given the potential toxicity and limited efﬁcacy
of these traditionally used drugs, new agents are being sought.
There is limited pharmacokinetic, efﬁcacy, toxicity and dosing
information available for the newer anticonvulsants (ie, levetirace-
tam and topiramate) in neonates—a recent review is available.37
Levetiracetam has attractive characteristics (ie, CYPP450 inde-
pendence, intravenous formulation available, 100% oral bioavail-
ability, no drug interactions and no protein binding) and is already
in off-label use in some centres. It is important to establish safety
and efﬁcacy, as evidenced by a recent trial into a similarly promis-
ing agent, bumetanide, which showed poor efﬁcacy and an
increase in hearing loss.38 A Cochrane review demonstrated that
there is no evidence to support the use of prophylactic anticonvul-
sants after perinatal asphyxia.39 Anticonvulsants are usually only
required in the ﬁrst week because seizures are ‘acute symptomatic’
and burn out with time. Occasionally longer-term therapy is
required in severely affected infants.
ENCEPHALOPATHY ASSESSMENT AND PROGNOSTICATION
A rapid clinical assessment will be required to determine eligibil-
ity for therapeutic hypothermia within the ﬁrst 6 hours of life.
Following this, regular reassessment and investigation is prudent
to determine progression of encephalopathy, exclude other
causes of encephalopathy and provide prognostic information to
families. A current review of the prognostic value of clinical
assessment and various investigations in HIE is available.40
Neurophysiology
EEG and aEEG are important tools for assessment of severity
of HIE, monitoring improvement over time and for recogni-
tion of seizures. Both have advantages and disadvantages.
aEEG is readily available at all times of the day on the neonatal
intensive care unit, can demonstrate background abnormalities
and sleep wake cycling, and is interpretable at the bedside.
aEEG can also detect a third of single seizures and two-thirds
of repetitive seizures, but those that are short lasting (<30 s)
or distant from the electrodes may be missed.41 Nevertheless,
aEEG is clearly superior to clinical detection of seizures
alone.42
Multichannel EEG is the gold standard, however technicians
are required to site EEG leads and may not be available at all
times of the day. Specialised neurophysiological interpretation
and prompt reporting of the EEG are also required and these
resources may not be available in all hospitals. Abnormalities of
background EEG pattern and the loss of sleep wake cycling are
commonly early after hypoxia ischaemia, and can be used to
assess clinical recovery and predict outcome. With therapeutic
hypothermia, the optimal time to assess aEEG for prognosis is
48 hours, with the return to a discontinuous normal voltage, or
a continuous normal voltage being associated with good
outcome, particularly if sleep wake cycling is present.43 A recent
meta-analysis of aEEG background and prediction of outcome is
available.44
Cranial ultrasound
Cranial ultrasound (CrUSS) is a simple, non-invasive and con-
venient initial imaging assessment for infants with HIE.
Cerebral oedema may be evident, with sparkly echo reﬂectance
of the parenchyma, obscuration of the sulcal markings and
closure of the ﬁssures. Slit-like ventricles are a normal ﬁnding in
term infants. In severe HIE there is increased echogenicity in
the thalamus and basal ganglia. However CrUSS is a poor prog-
nostic indicator, with only a 79% (95% CI 37% to 97%) sensi-
tivity and 55% (95% CI 35% to 70%) speciﬁcity for abnormal
outcome.40 Cerebral ﬂow velocity can also be measured using
Doppler studies. In healthy term infants in the ﬁrst 24 hours,
the average resistance index (RI) is 0.726 (SD 0.057). A reduc-
tion in RI to ≤0.55 is associated with poor outcome after peri-
natal asphyxia, although with cooling the positive predictive
value falls from 84% to only 60% (95% CI 45% to 74%).45
MRI and magnetic resonance spectroscopy (MRS)
MRI is the imaging modality of choice for assessment of injury
severity and prognostication in NE and a recent framework for
practice outlines the clinical indications, acquisitions and report-
ing for neonatal and fetal MRI.46 Changes on MRI scanning in
the neonatal period are reﬂective of pattern of injury (basal
ganglia predominant in ‘acute-total’, watershed predominant in
‘prolonged-partial’ or widespread injury in ‘severe-global’) and
correlate well with pattern of neurodevelopmental impair-
ment.47 MRI ﬁndings will change with time, and early scans
may miss the full extent of injury. The practice parameter con-
cludes that imaging should include conventional structural T1
weighted and T2 weighted images, diffusion weighted images,
and, where available, single-voxel MRS and be performed
between 5 days and 14 days.46
Injury on conventional MRI (T1 and T2) within the ﬁrst
2 weeks of life is 98% (95% CI 80% to 100%) sensitive and
76% (95% CI 36% to 94%) speciﬁc for the prediction of long-
term outcome. Diffusion weighted imaging and the apparent
diffusion coefﬁcient may demonstrate abnormalities earlier than
conventional MRI, but they are of less prognostic value (sensi-
tivity 58% (95% CI 24% to 84%), speciﬁcity 89% (95% CI
62% to 98%); and sensitivity 79% (95% CI 50% to 93%), spe-
ciﬁcity 85% (95% CI 75 to 91) respectively).40
MRS is increasingly used as a quantitative tool both for clin-
ical and research prognostication. 1H MRS can be used to
measure peaks of N-acetylasparate (NAA), choline, creatine,
lactate and the relative ratios of each in the thalamus and basal
ganglia. In Thayyil et al’s48 meta-analysis, lactate/NAA >0.29
(0.24 to 0.4) had a sensitivity of 0.82 (95% CI 0.74 to 0.89)
and a speciﬁcity of 0.95 (95% CI 0.88 to 0.99) for predicting
an abnormal outcome. On further review of studies that mea-
sured both MRS and conventional MRI, Lac/NAA was more
speciﬁc (98% (95% CI 87% to 100%) vs 76% (95% CI 61% to
88%)) and equally as sensitive (86% (95% CI 72% to 95%) vs
80% (95% CI 65% to 90%) as conventional MRI for prediction
of long-term outcome.48
Therapeutic hypothermia signiﬁcantly reduced the number of
infants with abnormal MRI ﬁndings with a similar predictive
accuracy of abnormal MRI (day 8) for outcome in the TOBY
trial at 18 months for cooled and non-cooled infants.49 Recent
studies however suggest that following cooling a ‘normal’ MRI
may not always predict normal outcome accurately—Rollins
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et al50 describe a negative predictive value of a normal MRI of
74% in their series.
Near-infrared spectroscopy
Near-infrared spectroscopy can be used as a non-invasive bedside
tool to obtain real time information on changes in cerebral oxy-
genation and haemodynamics. Regional cerebral oxygenation
(SctO2) and cerebral blood volume are higher on day 1 in
infants with HIE with adverse outcomes compared with those
with a favourable outcome.51 52 Fractional tissue oxygen extrac-
tion remains stable in infants with normal outcome but
decreases after 24 hours in infants with adverse outcome.44
Wavelet coherence analysis has been used to assess the dynamic
status of cerebral autoregulation during therapeutic hypother-
mia in HIE. Based on this method, signiﬁcant in-phase and anti-
phase coherence between spontaneous oscillations in mean
arterial pressure and SctO2 were found; both appeared to be
related to worse clinical outcomes.53 These ﬁndings support the
feasibility of using this method to assess cerebral autoregulation
in neonates with HIE as well as using this as a short-term and
long-term outcome measure. Broadband near-infrared spectros-
copy (NIRS) measures concentration changes of the cyto-
chrome c oxidase (oxCCO) redox state. CCO is the terminal
electron acceptor within mitochondrial electron transport chain
and is responsible for >95% of ATP synthesis; preclinical
studies suggest a correlation between CCO and nucleoside tri-
phosphate/phosphate pool recovery after hypoxia ischaemia.54
Prechtl
Prechtl’s method on the qualitative method of general movements
(GMsA) is non-invasive observational assessment performed using
video or direct inspection while the infant is in quiet wakefulness.
General movements (GMs) are whole body movements believed
to be important for the development of voluntary motor path-
ways, and normally progress in two predictable developmental
stages. ‘Writhing movements’ are low-moderate speed ﬂuid move-
ments of the trunk and limbs, and occur up to 6–9 weeks. ‘Fidgety
movements’, are most evident at 12 weeks. Abnormalities of
writhing movements (poor repertoire or cramped synchronised)
and ﬁdgety movements (absent or abnormal) predict neurodeve-
lopmental outcome.55 In 259 high-risk (preterm and NE term)
infants, absent ﬁdgety movements at 12 weeks had 98% sensitivity
and 94% speciﬁcity for CP at 1 year.56 In smaller cohorts of term
asphyxia infants only, results are similar57 with abnormalities on
GMsA highly correlating with MRI abnormalities.58
Blood biomarkers
A key to improving outcome is the identiﬁcation of early bio-
markers of brain injury that can be used to direct interventions,
gauge treatment effects and provide prognostic information for
parental counselling. There is no serum biomarker in current
clinical use for NE, however. Various biomarkers of brain injury
in blood, urine and CSF have been proposed, including S100
calcium-binding protein B (S100B), glial ﬁbrillary acidic protein
(GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1),
creatine kinase brain band, neuron-speciﬁc enolase (NSE), mal-
ondialdehyde and proinﬂammatory cytokines. Massaro et al
have shown that elevated serum S100B and NSE levels mea-
sured during hypothermia are associated with neuroradiographic
and clinical evidence of brain injury in NE.59 Chalak et al60
were able to stratify HIE into mild, moderate and severe based
on cord blood GFAP and ubiquitin carboxy-terminal hydrolase
Table 2 Summary of preclinical and clinical trial studies on seven promising adjunct neuroprotective agents
Adjunct therapy Mode of action Examples of recent preclinical trials Clinical RCTs
Melatonin Endogenous hormone which entrains the circadian
rhythm at physiological doses. At high
pharmacological doses melatonin is a powerful
antioxidant and antiapoptotic agent.
Systematic review and meta-analysis of 400
adult rodents showed a 43% reduction in stroke
infarct size with melatonin.74 A piglet study
showed augmentation of brain protection with
high dose melatonin at 10 min and cooling
versus cooling alone.75
Oral melatonin (10 mg/kg/day 5 doses)
tablets crushed in 5 mL distilled water.
n=15 cooled, n=15 cooled plus
melatonin, n=15 controls.76
Erythropoietin (Epo) Acute actions: neurotrophic, anti-inflammatory,
antiapoptotic, antioxidant
Chronic actions: erythropoiesis, angiogenesis,
oligodendrogenesis, neurogenesis.
Non-human primate model—hypothermia+Epo
treatment improved outcomes in non-human
primates exposed to umbilical cord occlusion.77
NEAT trial—safety and PK.78
Phase II trial of hypothermia and Epo
showed less MRI injury and better
short-term outcome.79
Phase III trial is now underway in the
USA.
Xenon Inhibits NMDA signalling, antiapoptotic. Preclinical piglet studies showed benefit of
combined cooling and xenon compared with no
treatment.80 81
No evidence of short-term benefit with
xenon and cooling above cooling alone,
using MRS lactate/NAA as a surrogate
outcome.82
Argon GABA agonist and oxygen type properties.
Antiapoptotic.
Preclinical piglet study showed brain protection
on MRS and histology with 50% argon and
cooling compared with cooling alone.83
Phase II trials pending regulatory
approval.
Allopurinol Reduces free radical production and in high doses
acts as a free radical scavenger and free iron chelator.
Improved 31P MRS metabolites and MRI values
with allopurinol in piglets.84
ALBINO trial to start in Europe 2017—to
assess benefit of early allopurinol at
30 min plus cooling versus cooling alone.
Stem cells Paracrine signalling—not cellular integration or direct
proliferative effects.
Evidence of improved neurological outcome and
reduced histological injury.85
Autologous umbilical cord cells in HIE
demonstrated feasibility.86
Magnesium Prevention of excitatory injury by stabilisation of
neuronal membranes and blockade of excitatory
neurotransmitters, for example, glutamate.
Magnesium alone has not been protective in
piglet models of hypoxia.87 Combinations of
magnesium with cooling has shown benefit.88
Recent meta-analysis shows no evidence
of benefit.88
A multicentre pilot RCT reported safety
but no outcome data, larger RCT to
follow89
HIE, hypoxic-ischaemic encephalopathy; GABA, gamma-aminobutyric acid; MRS, magnetic resonance spectroscopy; NAA, N-acetylasparate; NMDA, N-methyl-D-aspartate; PK,
pharmacokinetics; RCT, randomised controlled trials.
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L1. These brain-speciﬁc proteins may be useful immediate bio-
markers of cerebral injury severity but still need to be independ-
ently validated in large cohorts before they are ready for clinical
implementation in practice.
NEUROPROTECTIVE THERAPY IN HIE
Therapeutic hypothermia
The key principle to postnatal therapeutic interventions is the
concept of delayed secondary injury. Following birth and resus-
citation, the neonatal brain has a period of partial recovery, fol-
lowed by a latent phase lasting 1–6 hours. In moderate to severe
encephalopathy the brain then enters a phase of secondary
injury with near complete mitochondrial energy production
failure, cytotoxic oedema, cell death and clinical deterioration
often with seizures. This occurs for approximately 6–15 hours
following the hypoxic-ischaemic event.61 The latent phase pro-
vides a therapeutic window during which therapy can be pro-
vided to prevent secondary injury.
Therapeutic hypothermia commenced during the latent phase
has been the most important recent innovation in the care of
HIE. Therapeutic hypothermia improves outcomes of death and
disability.62 63 Longer-term developmental outcomes are emer-
ging and support ﬁndings at 18–24 months.64 65 Eligibility cri-
teria for cooling differ slightly between the RCTs and now
between neonatal units. However, the overall principals are the
same—there should be evidence of recent intrapartum asphyxia
for the term or near-term infant and the infant should demon-
strate encephalopathy. Our practice is to use the TOBY trial eli-
gibility criteria.66
It is clear from available clinical and preclinical evidence that
moderate therapeutic hypothermia should be implemented as
soon as possible, before onset of secondary injury and continued
until this period of secondary energy failure has resolved.61
Cooling should be started as soon as possible. Infants cooled
within 3 hours of birth have better neurodevelopmental out-
comes compared with infants whose cooling commences
between 3 hours and 6 hours.67 Following 72 hours of cooling,
infants should be slowly rewarmed (0.5°/hour). This is based on
animal data showing increased seizures68 and increased cortical
apoptosis69 with rapid rewarming. Longer or deeper cooling to
<33.5° and/or for >72 hours has not been shown to be of
beneﬁt, and is harmful.70 71
Future neuroprotective adjuncts
The number needed to treat with therapeutic hypothermia for
an additional beneﬁcial outcome is 7 (95% CI 5 to 10) from 8
studies, 1344 infants.62 Importantly, this means there is still a
large number of infants for whom this therapy is ineffective.
Adjuvant therapy to hypothermia is a current focus of research
and has been reviewed in more detail elsewhere.72 73 Some of
the more promising neuroprotective agents, scored by an inter-
national group of neuroscientists81 include melatonin, erythro-
poietin, inhaled xenon and argon, allopurinol, stem cells,
cannabinoids and magnesium (table 2).
FOLLOW-UP
A review on the follow-up of survivors of term HIE discusses
the clinical and imaging diagnostic criteria for HIE, which are
essential to decisions about follow-up.90 The recommendations
for follow-up and intervention are based on the clinical condi-
tion of the infant at the time of discharge from intensive care,
including an assessment of feeding, vision, hearing and whether
seizures continue to be present. Although the number of
survivors from HIE is lower than the number of survivors of
extreme prematurity, the proportion of neonates with long-term
sequelae is higher. All neonates with Sarnat stages 2 (moderate)
and 3 (severe) should be enrolled in follow-up programmes.
Early assessments (at 4–8 months) focus on head growth,
general health and motor neurodevelopment. Assessments at
12–24 months focus on cognitive skills and language develop-
ment. Preschool assessments are also strongly recommended to
provide for the identiﬁcation of children requiring early educa-
tion programmes.
DOCUMENTATION AND MEDICOLEGAL MATTERS
Approximately 13% of infants with NE will go on to develop
CP. In the USA between 1985 and 2008, the brain-damaged
infant was the leading type of paediatric medicolegal claim.91 In
the UK between 2012 and 2013, health trusts spent £482
million on ‘maternity negligence’, a ﬁfth of the total maternity
health expenditure.92 While well recognised that the obstetrician
may be liable for the death or long-term disability supposedly
arising from negligence at the time of birth, increasingly, the
paediatrician is being taken to court. Reasons for malpractice
claims include, but are not limited to, substandard resuscitation
technique, failure to transfer an infant to a neonatal unit in a
timely manner and failure to refer for, or initiate therapeutic
hypothermia in a timely manner.91
The clinician must fully document the resuscitation of infants
with potential HIE. This should include time of arrival, a thor-
ough description of the infant’s clinical status as this evolves
during the ﬁrst minutes and hours of life, time of each resuscita-
tive intervention, cord and early blood gas parameters and most
importantly decisions made re therapeutic hypothermia. It
should be clearly stated why the infant is eligible or ineligible
for cooling, and at what time cooling commenced.
REDIRECTION OF CARE AND ORGAN DONATION
Mortality rates in moderate to severe HIE treated with thera-
peutic hypothermia, are ∼25%.62 Most deaths occur after redir-
ection of care, when clinical evidence supports brain death or
devastating neurological injury. Guidelines for the diagnosis of
brain death in the neonate are available;93 94,they are, however,
not often used. More commonly, clinicians and families agree to
cease life-sustaining therapy when clinical assessment supports
severe neurological injury—persisting encephalopathy and low
voltage aEEG after rewarming±severe injury on neuroimaging.
Organ donation, from severely affected HIE donors, is
becoming a possibility. In the USA, neonatal organ donation is
more established, while in the UK it is gaining momentum.95 In
one US cohort, profound central nervous system injury and/or
encephalopathy was the most common cause of death for poten-
tially eligible neonatal donation after cardiac death donors.96
Importantly, despite the global hypoxia ischaemia suffered in
HIE, organs such as the kidney usually recover once trans-
planted. Eligibility criteria for donation and organs harvested
differ between transplant centres. Commonly there are weight
restrictions (ie, >2 kg) and potential donor organs depend on
whether harvested before (ie, after brain death) or after circula-
tory death. Most cases of neonatal solid organ donation to date
are of en bloc kidneys to an adult donor, harvested after con-
ﬁrmation of circulatory death—as was the case for the ﬁrst neo-
natal organ donation in the UK in 2013.97 In the USA a
neonate with severe HIE donated her heart, liver and kidneys
after determination of brain death.98 To our knowledge, this has
yet to be performed in the UK, due, until recently, to the lack of
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guidelines for determining brain death in the neonate. A guide-
line for diagnosing brain death in infants less than 2 months has
recently been published by the UK Royal College of Paediatrics
and Child Health.94 Other impediments to neonatal organ
donation include a lack of awareness of available services and a
reluctance of staff to discuss donation with grieving families.
Families are increasingly aware of organ donation, and may be
the ﬁrst to raise the subject. Our advice is to always consider
organ donation, discuss with your local transplant service as
soon as possible prior to redirection of care, and offer the
choice to the families of eligible infants.
THE NEXT 10 YEARS
The challenge over the next 5–10 years will be to assess (in phase
I and II trials) which adjunct therapy or combination is safe and
optimises hypothermic brain protection. Optimal care may
require tailoring treatments according to gender, genetic risk,
injury severity and inﬂammatory status. Early biomarkers, once
validated, will allow infants to be stratiﬁed and treatment effects
to be assessed. Rescue treatment may be needed in some infants
not responding to cooling. Until now, treatments have been tar-
geted to the early acute phase of injury; enhancing repair and
neurogenesis during the tertiary phase will require collaboration
between neonatologists and paediatric neurologists.
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